Michael Deininger

Sep 2, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

Correction to: Leukemia https://doi.org/10.1038/s41375-024-02159-0, published online 29 January 2024Following publication of the article, the authors realized that several data points in Figure S3B and the accompanying manuscript text were incorrect. This oversight has been addressed and the corrected figure has been added. 1.

Jun 20, 2024 | onclive.com | Michael Deininger

CommentaryVideoJune 20, 2024Author(s):Michael Deininger, MD, PhD, discusses 4-year outcomes with ponatinib in patients with chronic myeloid leukemia harboring a T315I mutation.

May 16, 2024 | nature.com | Jorge Cortés |Koji Sasaki |Timothy Hughes |Michael J. Mauro |Andreas Hochhaus |Michael C. Heinrich | +5 more

AbstractAsciminib targets the BCR::ABL1 myristoyl pocket, maintaining activity against BCR::ABL1T315I, which is resistant to most approved adenosine triphosphate–competitive tyrosine kinase inhibitors. We report updated phase I results (NCT02081378) assessing safety/tolerability and antileukemic activity of asciminib monotherapy 200 mg twice daily in 48 heavily pretreated patients with T315I-mutated chronic-phase chronic myeloid leukemia (CML-CP; data cutoff: January 6, 2021).

Jan 29, 2024 | nature.com | Elias Jabbour |Jane F. Apperley |Jorge Cortés |Michael Deininger |Elisabetta Abruzzese |Daniel DeAngelo | +2 more

AbstractPonatinib, the only approved all known-BCR::ABL1 inhibitor, is a third-generation tyrosine-kinase inhibitor (TKI) designed to inhibit BCR::ABL1 with or without any single resistance mutation, including T315I, and induced robust and durable responses at 45 mg/day in patients with CP-CML resistant to second-generation TKIs in the PACE trial.

Aug 29, 2023 | medscape.com | Michael J. Mauro |Michael Deininger

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael J. Mauro, MD: Hello. I'm Dr Michael Mauro and welcome to the Medscape InDiscussion podcast series on chronic myeloid leukemia (CML).